CCSB (1762) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 中化生

CCSB (1762) reported revenue of NT$94.6 million for Oct 2026, +598.5% year on year and +36.9% from the previous month. Revenue for Jan–Oct 2026 was NT$979 million (+38.9% year on year).

Year-on-year revenue growth: 4 months in a row. →

In Oct 2026, it ranked No. 79 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$77.1 million24/10Nov 2024 NT$103.6 millionDec 2024 NT$105.6 millionJan 2025 NT$90.6 millionFeb 2025 NT$39.4 million25/02Mar 2025 NT$62.9 millionApr 2025 NT$74.4 millionMay 2025 NT$99.5 millionJun 2025 NT$170.1 million25/06Jul 2025 NT$72.8 millionAug 2025 NT$45.4 millionSep 2025 NT$36.3 millionOct 2025 NT$13.5 million25/10Nov 2025 NT$42 millionDec 2025 NT$57.9 millionJan 2026 NT$126.9 millionFeb 2026 NT$102.9 million26/02Mar 2026 NT$131.4 millionApr 2026 NT$131 millionMay 2026 NT$72.4 millionJun 2026 NT$101.8 million26/06Jul 2026 NT$89.8 millionAug 2026 NT$59.1 millionSep 2026 NT$69.1 millionOct 2026 NT$94.6 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$94.6 million+598.5%+36.9%
Sep 2026NT$69.1 million+90.5%+17.0%
Aug 2026NT$59.1 million+30.3%-34.2%
Jul 2026NT$89.8 million+23.2%-11.8%
Jun 2026NT$101.8 million-40.2%+40.5%
May 2026NT$72.4 million-27.2%-44.7%
Apr 2026NT$131 million+76.0%-0.3%
Mar 2026NT$131.4 million+108.9%+27.8%
Feb 2026NT$102.9 million+161.3%-18.9%
Jan 2026NT$126.9 million+40.0%+119.1%
Dec 2025NT$57.9 million-45.2%+38.0%
Nov 2025NT$42 million-59.5%+209.7%
Oct 2025NT$13.5 million-82.4%-62.7%
Sep 2025NT$36.3 million-70.7%-20.0%
Aug 2025NT$45.4 million-70.9%-37.7%
Jul 2025NT$72.8 million+6.0%-57.2%
Jun 2025NT$170.1 million-1.3%+71.0%
May 2025NT$99.5 million-40.3%+33.7%
Apr 2025NT$74.4 million-39.1%+18.3%
Mar 2025NT$62.9 million-30.6%+59.8%
Feb 2025NT$39.4 million-55.9%-56.6%
Jan 2025NT$90.6 million+26.4%-14.2%
Dec 2024NT$105.6 million-10.2%+1.9%
Nov 2024NT$103.6 million-32.6%+34.3%
Oct 2024NT$77.1 million-58.1%-37.6%

Jan–Oct 2026 cumulative: NT$979 million (+38.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: CCSB vs PEC / CCSB vs Lotus Pharm / CCSB vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

單月營收較去年同期增加,主係RAPA、EPAE及CAS產品銷售較去年同期增加。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16